Welcome to our dedicated page for I-Mab news (Ticker: IMAB), a resource for investors and traders seeking the latest updates and insights on I-Mab stock.
I-Mab (NASDAQ: IMAB), now known as NovaBridge Biosciences, generates a steady flow of news as a U.S.-based, global biotech company focused on precision immuno-oncology. Investors following IMAB-related headlines can track how the company advances its lead Claudin 18.2 x 4-1BB bispecific antibody, givastomig, and other pipeline assets through clinical milestones, strategic transactions, and capital markets activity.
News coverage commonly highlights clinical data from Phase 1 and Phase 1b studies of givastomig in Claudin 18.2-positive gastric and gastroesophageal cancers, including monotherapy results and combination regimens with immunochemotherapy in the first-line metastatic setting. Company announcements describe objective response rates, safety findings, and study design details from presentations at major oncology conferences such as ESMO GI and the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting.
Beyond clinical readouts, IMAB news items also cover the company’s broader transformation into a global biotech platform under the NovaBridge Biosciences name. Releases discuss the adoption of a hub-and-spoke business model, the formation of subsidiaries like Visara, Inc. for VIS-101 in ophthalmology, and strategic agreements with partners including ABL Bio, AffaMed Therapeutics, AskGene Pharma, and Everest Medicines. Capital markets updates, such as underwritten offerings of American Depositary Shares and intentions to pursue a dual listing on the Hong Kong Stock Exchange, are also key themes.
On this news page, readers can review company press releases, SEC-referenced announcements, and other IMAB-related updates in one place. For investors and researchers, regularly checking this feed offers insight into clinical progress, partnership activity, governance changes, and financing events that shape the outlook for I-Mab’s, and NovaBridge Biosciences’, oncology and ophthalmology programs.
I-Mab (Nasdaq: IMAB) announced interim results from its clinical trial of lemzoparlimab, a CD47 antibody, in combination with rituximab for heavily treated patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). The study reported safety and tolerability with no need for a priming dose, and an overall response rate of 71%, with 4 complete responses among 7 evaluable patients. The ongoing study aims to expand patient enrollment for further evaluation. I-Mab continues to accelerate the clinical development of lemzoparlimab both in the U.S. and China.
I-Mab (Nasdaq: IMAB) announced an investor call scheduled for December 14, 2021, at 8:00 a.m. EST to discuss recent clinical data on lemzoparlimab combined with rituximab for treating relapsed or refractory non-Hodgkin's lymphoma. The company is focused on developing lemzoparlimab, a novel CD47 antibody designed to minimize side effects typically associated with this class of drugs. Ongoing studies in the U.S. and China aim to explore its efficacy across various malignancies, which could pave the way for future registrational trials.
I-Mab (Nasdaq: IMAB) announced the dosing of the first patient in a U.S. Phase I study of Protollin, an investigational drug for Alzheimer's disease. Conducted by Brigham and Women's Hospital, this randomized, double-blind trial assesses the safety and immune effects of Protollin on early symptomatic Alzheimer’s patients. The drug is designed to stimulate the innate immune system to combat beta amyloid plaques. Following FDA's acceptance of its IND submission in July 2021, this marks a significant milestone in developing new Alzheimer’s therapies.
I-Mab (Nasdaq: IMAB) announced its Board of Directors approved a motion for a dual listing of the company's ordinary shares on The Main Board of The Stock Exchange of Hong Kong Limited. The move is subject to market conditions, further Board approvals, and necessary regulatory clearances. I-Mab aims to enhance its global presence and facilitate capital raising through this initiative. As a clinical-stage biopharmaceutical company, I-Mab focuses on developing novel biologics for immuno-oncology and autoimmune diseases, supported by a robust pipeline of drug candidates.
I-Mab (Nasdaq: IMAB) announced the dosing of the first two patients in the U.S. phase 2 clinical study of its CD73 antibody, uliledlimab (TJD5), combined with atezolizumab (Tecentriq®) for patients with advanced ovarian cancer and other solid tumors. The study aims to evaluate uliledlimab's therapeutic potential and biomarkers in immune-resistant cancer types. Previous phase 1 trials showed favorable safety and promising efficacy. I-Mab is concurrently advancing uliledlimab’s development in China, indicating a robust strategy for global clinical advancement.
I-Mab (Nasdaq: IMAB) has formed a strategic partnership with Jumpcan Pharmaceutical Group to commercialize eftansomatropin alfa in mainland China. The deal is valued at up to RMB 2.016 billion (approximately $315 million) and includes an upfront payment of RMB 224 million (around $35 million). This collaboration is aimed at enhancing I-Mab’s commercialization efforts, with Jumpcan managing product distribution, targeting over 23,000 hospitals. Eftansomatropin alfa is in Phase 3 trials for pediatric growth hormone deficiency and offers a promising alternative to daily injections.
I-Mab (Nasdaq: IMAB) and ABL Bio announced promising preclinical data on their bispecific antibodies TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the SITC Annual Meeting. Both candidates are currently in Phase 1 clinical trials in the U.S. The data indicates enhanced anti-tumor activity and a favorable safety profile, potentially addressing dose-limiting toxicities associated with 4-1BB targeting drugs. The studies demonstrate significant immune responses and minimal systemic toxicity, positioning these candidates as innovative therapies for cancer treatment.
I-Mab (Nasdaq: IMAB) has announced a strategic collaboration with Roche Diagnostics to co-develop companion diagnostics (CDx) solutions aimed at enhancing the efficiency of biologics R&D. This partnership, unveiled at the Fourth China International Import Expo in Shanghai, will leverage Roche's technology to improve patient selection and drug efficacy. The collaboration is intended to fast-track I-Mab's innovative pipeline for potential cancer treatments, aligning with the company's goal to become a fully integrated global biopharmaceutical entity.
I-Mab (Nasdaq: IMAB) announced that initial clinical results of its differentiated CD47 monoclonal antibody, lemzoparlimab, will be presented at the ASH 2021 Annual Meeting from December 11-14, 2021. The trial is assessing lemzoparlimab's safety and efficacy in combination with rituximab for patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). This ongoing multi-center trial includes sites in the U.S. and China. I-Mab plans to host an investor call on December 14, 2021, to discuss these results.
I-Mab (Nasdaq: IMAB), a biopharmaceutical company, announced its participation in several healthcare conferences in November 2021. Notable events include the Goldman Sachs Asia Pacific Healthcare Forum, Jefferies London Healthcare Conference, BioCentury-BayHelix China Healthcare Summit, Morgan Stanley Asia Pacific Summit, and Piper Sandler Healthcare Conference. Key management personnel, including Dr. Jingwu Zang and Dr. Joan Huaqiong Shen, will represent the company in various discussions. I-Mab's focus remains on advancing its innovative pipeline in immuno-oncology and autoimmune diseases.